Answers are grounded in this paper and cite their sources.
Plasmodium vivax intervention trials customarily report uncorrected treatment failure rates. Application of recrudescence-reinfection genotyping and drug resistance single-nucleotide polymorphism typing to a 4-arm comparative efficacy trial illustrated that molecular approaches can assist in understanding the relative contributions of true drug resistance (recurrent with same genotype) and new infections to treatment failure. The PCR-corrected adequate clinical and parasitologic response may constitute an informative secondary endpoint in future P. vivax drug trials.
No takes yet. Share an insight, caveat, or question.
Barnadas et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: